This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Harlan, L. C. Articles by Trimble, E. L. Search for Related Content PubMed PubMed Citation Articles by Harlan, L. C. Articles by Trimble, E. L. Social Bookmarking                            What's this?

Trends in Surgery and Chemotherapy for Women Diagnosed With Ovarian Cancer in the United States

From the Applied Research Program, Surveillance Research Program, and Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD.

Address reprint requests to Linda C. Harlan, PhD, National Cancer Institute, 6130 Executive Blvd, MSC 7344, Bethesda, MD 20892-7344; e-mail: lh50w{at}nih.gov.

Purpose: We examined patterns of care in a population-based sample of 601 ovarian cancer patients diagnosed in 1991, and a sample of 566 women was selected in 1996 to examine trends in care.

Patients and Methods: Patient cases were sampled from within the Surveillance, Epidemiology, and End Results program. Medical records were reabstracted, and treatment data were verified with the treating physician.

Results: Across these two time periods, the percentage of women with presumptive stage I, II, and IV disease who received lymph node dissection increased. However, a significant number still were not precisely staged. More than 65% of women with ovarian cancer were given cyclophosphamide in 1991 compared with about 14% in 1996. Paclitaxel increased from 1% to 62% during that time. After adjusting for age, race or ethnicity, registry, income, insurance status, Charlson score, residency training program, and marital status, women with early-stage disease were significantly more often given National Institutes of Health Consensus Development Conference guideline therapy in 1996 than in 1991. However, for women with stage III and IV disease, the use of guideline therapy did not significantly increase. Older women and minorities consistently received less guideline therapy, and the lack of private insurance was an impediment for both Hispanic and non-Hispanic black women.

Conclusion: Despite guidelines presented by several organizations, significant numbers of women with ovarian cancer are not being provided with appropriate care. This is particularly true for older and minority women, especially those without private insurance. Educational strategies must be devised to increase the number of women receiving guideline therapy and decrease disparities across population groups.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				T. J. Duncan, A. Al-Attar, P. Rolland, I. V. Scott, S. Deen, D. T.Y. Liu, I. Spendlove, and L. G. Durrant Vascular Endothelial Growth Factor Expression in Ovarian Cancer: A Model for Targeted Use of Novel Therapies? Clin. Cancer Res., May 15, 2008; 14(10): 3030 - 3035. [Abstract] [Full Text] [PDF]

				M. Markman Concept of Optimal Surgical Cytoreduction in Advanced Ovarian Cancer: A Brief Critique and a Call for Action J. Clin. Oncol., September 20, 2007; 25(27): 4168 - 4170. [Full Text] [PDF]

				W. E. Winter III, G. L. Maxwell, C. Tian, J. W. Carlson, R. F. Ozols, P. G. Rose, M. Markman, D. K. Armstrong, F. Muggia, and W. P. McGuire Prognostic Factors for Stage III Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study J. Clin. Oncol., August 20, 2007; 25(24): 3621 - 3627. [Abstract] [Full Text] [PDF]

				C. Bouchardy, E. Rapiti, S. Blagojevic, A.-T. Vlastos, and G. Vlastos Older Female Cancer Patients: Importance, Causes, and Consequences of Undertreatment J. Clin. Oncol., May 10, 2007; 25(14): 1858 - 1869. [Abstract] [Full Text] [PDF]

				F Hilpert, A du Bois, E. Greimel, J Hedderich, G Krause, L Venhoff, S Loibl, and J Pfisterer Feasibility, toxicity and quality of life of first-line chemotherapy with platinum/paclitaxel in elderly patients aged >=70 years with advanced ovarian cancer--a study by the AGO OVAR Germany Ann. Onc., February 1, 2007; 18(2): 282 - 287. [Abstract] [Full Text] [PDF]

				E. L. Trimble and M. C. Christian Cancer treatment and the older patient. Clin. Cancer Res., April 1, 2006; 12(7): 1956 - 1957. [Full Text] [PDF]

				C. C. Earle, D. Schrag, B. A. Neville, K. R. Yabroff, M. Topor, A. Fahey, E. L. Trimble, D. C. Bodurka, R. E. Bristow, M. Carney, et al. Effect of Surgeon Specialty on Processes of Care and Outcomes for Ovarian Cancer Patients J Natl Cancer Inst, February 1, 2006; 98(3): 172 - 180. [Abstract] [Full Text] [PDF]

				B. K. Edwards, M. L. Brown, P. A. Wingo, H. L. Howe, E. Ward, L. A. G. Ries, D. Schrag, P. M. Jamison, A. Jemal, X. C. Wu, et al. Annual Report to the Nation on the Status of Cancer, 1975-2002, Featuring Population-Based Trends in Cancer Treatment J Natl Cancer Inst, October 5, 2005; 97(19): 1407 - 1427. [Abstract] [Full Text] [PDF]

				S. Paramasivam, L. Tripcony, A. Crandon, M. Quinn, I. Hammond, D. Marsden, A. Proietto, M. Davy, J. Carter, J. Nicklin, et al. Prognostic Importance of Preoperative CA-125 in International Federation of Gynecology and Obstetrics Stage I Epithelial Ovarian Cancer: An Australian Multicenter Study J. Clin. Oncol., September 1, 2005; 23(25): 5938 - 5942. [Abstract] [Full Text] [PDF]

				A. L. Potosky, S. Saxman, R. B. Wallace, and C. F. Lynch Population Variations in the Initial Treatment of Non-Small-Cell Lung Cancer J. Clin. Oncol., August 15, 2004; 22(16): 3261 - 3268. [Abstract] [Full Text] [PDF]